"Beverly Hills Cancer Center has world-class physicians who treat patients all over Los Angeles, its surrounding areas as well as world-wide. We vigorously strive to be among the world’s best cancer centers in our pursuit of total health and wellness by delivering leading-edge medicine in a truly compassionate manner. By combining breakthrough research with advanced diagnostic technologies and a variety of treatment modalities, our dedicated medical professionals provide uniquely comprehensive care to those with cancer and other life-threatening diseases."

During the past decade, Beverly Hills Cancer Center conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 17 clinical trials were completed, i.e. on average, 40.5% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 14 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Beverly Hills Cancer Center" #1 sponsor was "Pfizer" with 8 trials, followed by "Eli Lilly and Company" with 6 trials sponsored, "G1 Therapeutics, Inc." with 4 trials sponsored, "Mirati Therapeutics Inc." with 4 trials sponsored and "Novartis Pharmaceuticals" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Beverly Hills Cancer Center" #1 collaborator was "ARMO BioSciences" with 2 trials as a collaborator, "Astellas Pharma Inc" with 2 trials as a collaborator, "BeiGene" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Beverly Hills Cancer Center" are "Breast Cancer" (7 trials), "Metastatic Breast Cancer" (5 trials), "Colorectal Cancer" (4 trials), "Advanced Breast Cancer" (3 trials) and "Breast Neoplasms" (3 trials). Many other conditions were trialed in "Beverly Hills Cancer Center" in a lesser frequency.

Most popular intervention types in "Beverly Hills Cancer Center" are "Drug" (47 trials), "Biological" (6 trials), "Other" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Fulvestrant" (5 trials), "Letrozole" (4 trials), "Nivolumab" (4 trials) and "Pembrolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Beverly Hills Cancer Center" are 42 trials for "All" genders, 5 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Beverly Hills Cancer Center". undefined are not yet recruiting, 10 are recruiting, 15 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 14 completed trials in Beverly Hills Cancer Center, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Beverly Hills Cancer Center, 11 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".